Clementia Pharmaceuticals Inc., of Montreal, said the data monitoring committee for the company's phase II adaptive-design, dose-ranging study of palovarotene for fibrodysplasia ossificans progressiva has completed a planned review of efficacy and safety data from the first cohort of patients in the study.